Abstract 4663: Combination of c-Met inhibitor tepotinib (MSC2156119J) and a third-generation EGFR inhibitor can overcome double resistance mediated by EGFR T790M mutation and c-Met amplification in non-small cell lung cancer models

2016 ◽  
Author(s):  
Manja Friese-Hamim ◽  
Giuseppe Locatelli ◽  
Friedhelm Bladt
Keyword(s):  
Lung Cancer ◽  
Small Cell ◽  
Third Generation ◽  
Egfr Inhibitor ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Cancer Models ◽  
Met Amplification ◽  
Met Inhibitor ◽  
Egfr T790m

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation

Lung Cancer ◽  
2019 ◽  
Vol 127 ◽  
pp. 96-102 ◽  
Author(s):  
Jean Bernard Auliac ◽  
Maurice Pérol ◽  
David Planchard ◽  
Isabelle Monnet ◽  
Marie Wislez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real Life ◽  
Small Cell ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Pretreated Patients ◽  
Egfr T790m

scholarly journals Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer

2016 ◽  
Vol 23 (9) ◽  
pp. 2131-2135 ◽  
Author(s):  
Sean Khozin ◽  
Chana Weinstock ◽  
Gideon M. Blumenthal ◽  
Joyce Cheng ◽  
Kun He ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Egfr T790m
Sign in / Sign up

Export Citation Format

Share Document